600 related articles for article (PubMed ID: 25882777)
1. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
Ou SH; Klempner SJ; Azada MC; Rausei-Mills V; Duma C
Lung Cancer; 2015 Jun; 88(3):355-9. PubMed ID: 25882777
[TBL] [Abstract][Full Text] [Related]
2. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
6. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
8. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
9. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
10. Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Santarpia M; Altavilla G; Rosell R
Expert Rev Respir Med; 2015 Jun; 9(3):255-68. PubMed ID: 25652176
[TBL] [Abstract][Full Text] [Related]
11. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.
Gainor JF; Sherman CA; Willoughby K; Logan J; Kennedy E; Brastianos PK; Chi AS; Shaw AT
J Thorac Oncol; 2015 Feb; 10(2):232-6. PubMed ID: 25526238
[TBL] [Abstract][Full Text] [Related]
12. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
Metro G; Lunardi G; Bennati C; Chiarini P; Sperduti I; Ricciuti B; Marcomigni L; Costa C; Crinò L; Floridi P; Gori S; Chiari R
J Neurooncol; 2016 Sep; 129(2):355-61. PubMed ID: 27324494
[TBL] [Abstract][Full Text] [Related]
13. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K
Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
[TBL] [Abstract][Full Text] [Related]
14. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
[TBL] [Abstract][Full Text] [Related]
15. Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.
Gainor JF; Chi AS; Logan J; Hu R; Oh KS; Brastianos PK; Shih HA; Shaw AT
J Thorac Oncol; 2016 Feb; 11(2):256-60. PubMed ID: 26845119
[TBL] [Abstract][Full Text] [Related]
16. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
Burudpakdee C; Wong W; Seetasith A; Corvino FA; Yeh W; Gubens M
Lung Cancer; 2018 May; 119():103-111. PubMed ID: 29656744
[TBL] [Abstract][Full Text] [Related]
17. Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Tamura T; Kiura K; Seto T; Nakagawa K; Maemondo M; Inoue A; Hida T; Yoshioka H; Harada M; Ohe Y; Nogami N; Murakami H; Kuriki H; Shimada T; Tanaka T; Takeuchi K; Nishio M
J Clin Oncol; 2017 May; 35(14):1515-1521. PubMed ID: 28296581
[TBL] [Abstract][Full Text] [Related]
18. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.
Lin JJ; Jiang GY; Joshipura N; Ackil J; Digumarthy SR; Rincon SP; Yeap BY; Gainor JF; Shaw AT
J Thorac Oncol; 2019 Apr; 14(4):683-690. PubMed ID: 30529198
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic Brain Radiation Necrosis in an Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Patient After Fractionated Stereotactic Radiotherapy While on Alectinib.
BalajiSubramanian S; Al Hajri T; Satyapal N; Laiq S; Al Hajri Z
Cureus; 2023 Mar; 15(3):e35952. PubMed ID: 37038567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]